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Abstract 
Poorly differentiated neuroendocrine carcinomas (PDNEC) are rare tumours that can originate from any site of the gastrointestinal tract 
exhibiting an overall aggressive behaviour that may vary between tumours according to the degree of cellular proliferation. The majority 
of PDNEC are locally advanced or metastatic at presentation, and are only infrequently associated with secretory hormonal syndromes. 
PDNEC exhibit aggressive histological features (high mitotic rate, high Ki67 labelling index and presence of necrosis) and are further 
subdivided into two morphological subgroups, small and large cell variants. As PDNEC express somatostatin receptors less frequently, 
somatostatin receptor scintigraphy is usually negative, whereas 18F-fluorodeoxyglucose positron emission tomography appears to be the 
best method of evaluating disease spread and guiding further treatment. PDNEC have traditionally been treated similarly to small cell 
lung carcinoma, although they show a number of different clinical and histopathologic features. First line systemic chemotherapy with 
a platinum-based agent and etoposide is used for patients with metastatic disease, leading to variable response rates that are often of relative 
short duration. Sequential or concurrent chemoradiation is recommended for patients with locoregional disease. In patients with localised 
disease, complete surgical resection should be offered followed by adjuvant treatment (chemotherapy with or without radiotherapy); the 
value of neoadjuvant chemotherapy has not been evaluated as yet. The role of second line therapies is evolving, with temozolomide being 
a promising agent. However, the majority of data regarding PDNEC is hampered by the small number of series and their retrospective 
nature, making it important that multicentre co-operative studies be performed. (Endokrynol Pol 2013; 64 (1): 60–72)
Key words: gastrointestinal (GI), poorly differentiated neuroendocrine carcinomas (PDNEC), Ki67 labelling index, etoposide, cisplatin, 
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Streszczenie 
Niskozróżnicowane raki neuroendokrynne (PDNEC, poorly differentiated neuroendocrine carcinomas) to rzadkie nowotwory, które mogą 
wywodzić się z dowolnego miejsca w przewodzie pokarmowym, cechując się ogólnie agresywnym przebiegiem uzależnionym od stopnia 
nasilenia proliferacji komórek nowotworowych. Większość przypadków PDNEC w momencie rozpoznania stanowią nowotwory miejscowo 
zaawansowane lub przerzutowe i rzadko towarzyszą im zespoły chorobowe związane z wydzielanymi przez te nowotwory hormonami. 
PDNEC cechują się agresywnym obrazem histopatologicznym (duża liczba figur podziału, wysoki wskaźnik aktywności proliferacyjnej 
Ki67 i obecność martwicy) i wyróżnia się wśród nich dwie podgrupy morfologiczne — odmianę drobnokomórkową i wielkokomórkową. 
Ponieważ w PDNEC rzadziej stwierdza się ekspresję receptorów somatostatynowych, scyntygrafia receptorów somatostatynowych zwy-
kle daje negatywne wyniki, natomiast pozytonowa tomografia emisyjna z 18F-fluorodeoksyglukozą wydaje się być najlepszą metodą do 
oceny rozległości choroby i  pomocną przy podejmowaniu decyzji dotyczących dalszego leczenia. PDNEC zwykle leczy się podobnie do 
drobnokomórkowego raka płuca, choć nowotwory te wykazują szereg różnic klinicznych i histopatologicznych. U pacjentów z chorobą 
rozsianą stosuje się układową chemioterapię pierwszego rzutu obejmującą pochodną platyny i etopozyd. Odsetek odpowiedzi na leczenie 
jest różny, a sama odpowiedź utrzymuje się względnie krótko. U pacjentów z chorobą lokoregionalną zaleca się stosowanie sekwencyjnej 
lub jednoczasowej chemioradioterapii. U pacjentów z chorobą zlokalizowaną stosuje się radykalne leczenie chirurgiczne z chemio- lub 
chemioradioterapią uzupełniającą. Nie ustalono dotychczas roli chemioterapii neoadiuwantowej. Schematy leczenia drugiego rzutu na 
razie ewoluują; obiecujący wydaje się być temozolomid. Wartość większości danych dotyczących PDNEC jest jednak ograniczona niezbyt 
dużą liczbą przypadków oraz ich retrospektywnym charakterem. Dlatego też tak ważne byłoby przeprowadzenie wieloośrodkowych 
badań kooperacyjnych. (Endokrynol Pol 2013; 64 (1): 60–72)
Słowa kluczowe: przewód pokarmowy, niskozróżnicowane raki neuroendokrynne (PDNEC), wskaźnik aktywności proliferacyjnej Ki67, etopozyd, 
cisplatyna, temozolomid
Introduction
Poorly differentiated neuroendocrine carcinomas (PD-
NEC) of the gastrointestinal (GI) tract are rare tumours 
composed of highly atypical, small-to-medium-sized 
tumour cells associated with necrosis, prominent an-
gioinvasion, and/or perineural invasion [1]. Tradition-
ally, small cell and the less common large cell lung car-
cinomas (SCLC and LCLC respectively), constitute the 
commonest sites of origin of PDNC; however, following 
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the newly introduced classification systems, carcinomas 
with prominent neuroendocrine (NE) differentiation 
can be detected in virtually all tissues [2]. PDNEC of the 
GI (GI-PDNEC) tract constitute the commonest location, 
accounting for 35–55% of all extra-pulmonary PDNEC 
mainly located in the oesophagus, stomach, pancreas 
and colon, but in up to 30% of GI-PDNEC no primary 
localisation is found [3, 4]. The recent World Health 
Organisation (WHO) classification system, along with 
others such as that of the European Neuroendocrine 
Tumour Society (ENETS), have highlighted the distinct 
nature of these tumours and the need to be distin-
guished from mixed exocrine-endocrine and exocrine 
tumours that contain only small numbers of endocrine 
cells [1, 4, 5]. Overall, the prognosis of GI-PDNEC is poor 
compared to other gastro-enteropancreatic neuroendo-
crine tumours (GEP-NETs) that, in their great majority, 
are well differentiated tumours (WDNET) exhibiting 
significantly high 5- and 10-year survival rates even in 
the presence of metastatic disease [6]. However, recent 
studies have shown that even within the group of 
PDNEC, clinical presentation, response to treatment 
and overall prognosis, although generally poor, may 
substantially differ between tumours [1, 3, 7–9].
Due to the rarity of GI-PDNEC there are very few 
large studies regarding their epidemiology, clinical pres-
entation, genetic background, histopathology, natural 
history and appropriate treatment [1, 3, 8–12]. Only 
recently a comprehensive multicentre retrospective 
study has provided some consistent data confirming 
their overall poor prognosis and also verified their 
heterogeneity [7]. 
In this review, we aim to present currently existing 
data regarding GI-PDNEC in an attempt to provide 
evidence-based information, when present, and estab-
lish a basis for the registration of these tumours. 
Epidemiology and histopathologic features
Epidemiology
Extra-pulmonary PDNEC are rare tumours that can 
originate anywhere in the GI tract, with a preponder-
ance in areas of squamous GI epithelium such as the 
oesophagus and anus [13]; in the jejunum and ileum 
these tumours represent only 1% of all NETs [13]. Be-
fore the introduction of recently devised classification 
systems, previous studies have regarded extra-pulmo-
nary SCC as uncommon malignant neoplasms with 
an incidence of 0.1–0.4% in the USA, accounting for 
2.5–5.0% of all SCC [3, 11]. Based on the previous clas-
sifications, approximately 544 cases had been reported 
and analysed in a comprehensive older review [3,14]. In 
a more recent analysis of the Surveillance, Epidemiol-
ogy and End Results (SEER) database, GI-PDNEC were 
found to have an incidence of 2/106 inhabitants/year 
[7, 8]. However, in these studies, mixed tumours with 
some neuroendocrine component were also included 
and there was no prospective registration of these ma-
lignancies. A large multicentre prospective study from 
Italy employing recent classification systems evaluated 
several clinico-pathological parameters in 297 patients 
with pancreatic NETs (pNETs) and confirmed that 
PDNEC of the pancreas are indeed rare neoplasms, 
constituting only 7.7% of the total cases of pNETs [15]. 
In the same cohort, the majority of pancreatic PDNEC 
were non-functioning (95%) and, in agreement with the 
aggressive nature of this disease, were diagnosed at an 
advanced stage (39% with Stage III and 61% with stage 
IV disease) [15]. Furthermore, studies including larger 
numbers of patients have indicated that the relative 
heterogeneity of prognosis and response to treatment 
of these tumours is probably related to distinct clinico-
pathological features such as the site of origin of the 
primary tumour, the value of Ki67 labelling (LI), and 
the expression of somatostatin receptors (sstr) [7, 16]. 
Due to their rarity, these tumours were initially 
considered to be similar to SCLC as they share common 
histopathologic features and also exert an aggressive 
behaviour [10, 13]. However, several studies have shown 
some differences at the molecular level, particularly as 
the apoptotic marker Bcl-2 has been found to be over-
expressed in approximately 75–95% of patients with 
SCLC compared to 33% in GI-PDNEC patients [3]. In 
addition, unlike SCLC, extra-pulmonary PDNEC show 
retention of both arms of Chromosome 3 [12]. Since 
such cytogenetic differences between these tumours do 
exist, clinical features and outcome following the same 
treatment could also exhibit substantial differences [1,9]. 
Indeed several studies have tried to directly compare 
several features of pulmonary and extra-pulmonary 
PDNEC, demonstrating specific differences [3, 11, 14] 
(Table I). 
Histopathologic and genetic features
PDNEC have been previously defined as poorly dif-
ferentiated endocrine carcinomas in order to delineate 
their difference from the majority of GEP-NETs that are 
well differentiated and slowly growing tumours [6]. 
The concept of differentiation is based on the grade (G) 
of the tumours, although there are subtle differences 
between these two entities [2]. Differentiation refers to 
the extent to which the neoplastic cells resemble their 
non-neoplastic counterparts; WDNETs exhibit char-
acteristic organoid arrangements of the tumour cells, 
with nesting, trabecular or gyriform patterns [1,2,9]. 
The cells are relatively uniform, producing abundant 
neurosecretory granules, as shown by the strong and 
diffuse immunoexpression of neuroendocrine markers 
62
Uptade in diagnosis and management of GI-PDNEC  Anna Koumarianou et al.
SZ
K
O
LE
N
IE
 
PO
D
Y
PL
O
M
O
W
E
Table I. Differences between pulmonary and extrapulmonary PDNEC
Tabela I. Różnice między PDNEC w lokalizacji płucnej i pozapłucnej
Extrapulmonary PDNEC Small cell lung cancer Large cell lung cancer 
Median age at  
presentation
62 years [3, 7, 10] 60 years [60] 60 years [61] 
Gender Males more common [3, 7, 10] Males more common but tend  
to become equal [62]
Male more common [63] 
Past medical and  
family history
No associations recorded Other heart or lung diseases related  
to smoking may coexist.  
No hereditary factors
No associations recorded
Symptoms Most commonly weight loss, 
abdominal pain and obstructive 
symptoms [3] 
Dyspnoea, cough, superior  
vena cava syndrome, hoarseness, 
stridor, dysphagia [64] 
Haemoptysis, chest pain, 
dyspnoea and cough [64]
Para-neoplastic  
syndrome 
Usually absent Cushing’s syndrome, syndrome  
of inappropriate secretion of 
antidiuretic hormone, Eaton-Lambert 
myasthenic syndrome [64] 
Para-neoplastic syndromes are 
absent [65] 
Alcohol / smoking No smoking history Smoking is the most common  
cause identified [66] 
Smoking [61] 
Staging system TNM staging [64] 7th edition TNM system, limited/
extended disease [64], IASLC [64]
7th edition TNM system Edge [64]
Work up Total body CT scans, bone scan, 
18F-FDG PET [13]
Total body CT scans, bone scan, 
baseline laboratory evaluation [64]
Total body CT scans, bone scan, 
baseline laboratory tests, 18F-FDG 
PET [64]
Origin Any GI tract Centrally located [64] Peripherally located [61] 
Genetic profile Abnormal expression of p53, Rb,  
bcl-2, p27 [24, 67] 
Expression of tumour suppressor  
genes (e.g. p53) and protoncogenes 
(e.g. Bcl-1, IGF-1R) is altered [68]
Activation of the c-met pathway 
[69]
Histological workup Tissue biopsy is a requirement. 
Cellular polymorphism, tumour 
necrosis, high mitotic rate and Ki67 
[70]
Tissue biopsy is not easily  
diagnostic under the light microscope. 
Immunohistochemistry may be 
positive for cytokeratin markers 
AE1/AE3, CD56, chromogranin, and 
synaptophysin. TTF-1 70–80% positive, 
Ki-67 80–100% positive [64]
Tissue biopsy is a requirement. 
Neuroendocrine architecture 
is not always present and 
immunohistochemistry with 
synaptophysin, chromogranin  
NCAM and CD56 is necessary.  
TTF-1 positive in 41-75%. Ki-67 
50-100% [61]. Positive keratin 7 
and 18, E- and P-cadherins, beta-
catenin,  
villin 1, retinoblastoma protein,  
c-met and alpha-enolase [71]
Surgery Important treatment in limited 
disease [3]
Not an option in limited disease unless 
very limited disease to T1/T2 N0 
[72] Nodal evaluation is required by 
diagnostic imaging such as PET-CT, 
mediastinoscopy or endobronchial 
ultrasound-guided transbronchial 
needle aspiration [73]
The role of surgery is not fully 
evaluated in this disease.  
Five-year survival varies between 
13% and 57% [74]
Chemotherapy  
adjuvant/first line
Platinum-based and etoposide  
[46, 47]
Cisplatinum and etoposide [75] Cisplatinum etoposide for adjuvant 
[76] and first line [77]
Chemotherapy  
second line
Irinotecan, topotecan [78] Topotecan intravenously, topotecan 
orally, irinotecan, CAV intravenously 
(Cyclophosphamide Adriamycin 
Vincristin) [64]
No records in the literature 
except a few responses after 
rechallenging with platinum and 
etoposide [79]
PDNEC — poorly differentiated neuroendocrine carcinomas; 18F-FDG PET — 18F-fluorodeoxyglucose positron emission tomography; CT — computed 
tomography; GI — gastrointestinal tract
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such as chromogranin A (CgA) and synaptophysin [1,9] 
(Fig. 1). In contrast, PDNEC exhibit a more diffuse ar-
chitecture, irregular nuclei with less cytoplasmic granu-
larity whereas immunoexpression of neuroendocrine 
markers is relatively limited [1,9] (Fig. 2). In this con-
cept, grading of the tumour has been introduced as an 
index of biologic aggressiveness, based on the number 
of mitoses, presence of necrosis and/or Ki67 LI, where 
all PDNEC are considered as high grade (G3) tumours 
being extremely aggressive, whereas intermediate grade 
(G2) tumours have a less predictable course. (Table II, 
III and Fig. 3). It has recently been proposed that there 
may be an overlap in clinical behaviour, response to 
treatment and overall prognosis even within tumours 
belonging to the same grading group. This holds true 
particularly between G2 tumours with high Ki67 LI values 
and G3 tumours with Ki67 LI values close to the 20% limit 
compared to those with higher values, particularly when 
the Ki67 values are greater than 60% [2, 17] (Table II). This 
has recently been confirmed by a number of studies 
Table I. Differences between pulmonary and extrapulmonary PDNEC
Tabela I. Różnice między PDNEC w lokalizacji płucnej i pozapłucnej
Extrapulmonary PDNEC Small cell lung cancer Large cell lung cancer 
Radiotherapy Rectal cancer [13] In limited disease, thoracic and 
cranial prophylactic irradiation [80]
Sparse data but National 
Comprehensive Cancer Network 
guidelines recommend its use 
as for non small cell lung cancer 
[81]
Peptide Receptor  
Radiotherapy
Usually not expressing 
somatostatin receptors
Not applicable as it is a high grade 
tumour 
No published data
Somatostatin  
analogues
Not useful as not expressing 
somatostatin receptors. Role in 
functional syndromes
Not applicable as it is a high grade 
tumour not expressing somatostatin 
receptors
No published trial but a study 
using 68Ga-DOTATATE, a novel 
selective somatostatin receptor 2 
PET ligand, was negative [82] 
Targeted therapy No data available Experimental. Promising data from IGF-
1R inhibitors [83]
Experimental. Promising data from 
met inhibitors [84] 
Response to  
treatment
67% [46] 55–73% [85] 50–68% [86] 
Overall five-year  
survival 
Depends on primary, stage and 
treatment, but overall very poor [7, 
87]
 6% http://www.cancer.org/
Research/CancerFactsFigures/
CancerFactsFigures/cancer-facts-and-
figures-2010
13% [74]
Figure 1. Well-differentiated neuroendocrine tumour
Rycina 1. Wysokozróżnicowane nowotwory neuroendokrynne 
Figure 2. Poorly differentiated neuroendocrine carcinoma
Rycina 2. Niskozróżnicowane raki neuroendokrynne
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to-medium-sized tumour cells growing in a solid sheet, 
exhibiting prominent angioinvasion and lymph node/ 
/distant metastases [19]. Tumour cells are strongly posi-
tive for cytosolic markers of neuroendocrine differentia-
tion, such as neuron specific enolase (NSE) and PGP 9.5 
protein, but exert relatively weak or absent positivity for 
CgA [20]. Positive CgA staining indicates a more mature 
tumour and the presence of both synaptophysin and CgA 
is regarded as a relatively good prognostic sign [8, 21].
However, this feature has been shown not to be of 
clinical significance in a recent study [7]. Histopathologi-
cally, GI-small cell carcinoma (SCC) is indistinguishable 
from pulmonary SCC with small cell tumour size, ap-
Table II. Neuroendocrine classification: traditional versus current
Tabela II. Tradycyjna i aktualna klasyfikacja nowotworów neuroendokrynnych
Mitotic count/10HPF* Ki67 index 
(%)**
Traditional classification ENETS/WHO classification
< 2 ≤ 2 Carcinoid, islet cell, pancreatic (neuro)endocrine 
tumour
Neuroendocrine tumour grade 1
2–20 3–20 Carcinoid, atypical carcinoid***, islet cell, 
pancreatic (neuro)endocrine tumour
Neuroendocrine tumour grade 2
> 20 > 20 Small cell carcinoma
Large cell neuroendocrine carcinoma
Neuroendocrine carcinoma,  
grade 3, small cell
Neuroendocrine carcinoma  
grade 3, large cell
HPF — high-power field; ENETS — European Neuroendocrine Tumour Society; *HPF = 2 mm2; at least 40 fields (at X magnification) in areas of highest 
mitotic density. Cutoff values were taken from American Joint Committee on Cancer staging system (seventh edition); **MIB1 antibody; percentage of 
2,000 tumour cells in areas of highest nuclear labelling. Cutoff values were taken from American Joint Committee on Cancer staging system (seventh 
edition); ***The term atypical carcinoid only applies to immediate-grade neuroendocrine tumour of the lung
Table III. Lung versus gastroenteropancreatic neuroendocrine tumours (GEP-NETs) classification system
Tabela III. Nowotwory neuroendokrynne płuc i nowotwory neuroendokrynne układu pokarmowego (GEP-NET)
Grade Lung and  
Thymus 
(WHO)
GEP-NETs 
(ENETS)
GEP-NETs 
(WHO)
Lung and thymus Pancreas
Low grade Carcinoid  
tumour
Neuroendocrine tumour, 
grade 1 
Neuroendocrine 
neoplasm, grade 1 
Neuroendocrine 
carcinoma, grade 1
Well-differentiated 
endocrine 
neoplasm, low 
grade
Intermediate  
grade
Atypical  
carcinoid  
tumour
Neuroendocrine tumour, 
grade 2 
Neuroendocrine 
neoplasm, grade 2 
Neuroendocrine 
carcinoma, grade 1
Well-differentiated 
endocrine 
neoplasm, 
intermediate grade
High grade Small cell 
carcinoma 
Large cell 
neuroendocrine 
carcinoma
Neuroendocrine 
carcinoma, grade 3,  
small cell carcinoma 
Neuroendocrine 
carcinoma, grade 3,  
large cell carcinoma
Neuroendocrine 
carcinoma, grade 3,  
small cell carcinoma 
Neuroendocrine 
carcinoma, grade 3,  
large cell carcinoma
Neuroendocrine 
carcinoma, grade 3, 
small cell carcinoma 
Neuroendocrine 
carcinoma, grade 3, 
large cell carcinoma
Poorly 
differentiated 
endocrine 
carcinoma, small 
cell carcinoma 
Poorly 
differentiated 
endocrine 
carcinoma, large 
cell carcinoma
Adapted from Klimstra D et al, ’Pancreas’ 2010; 39: 707–712
that have evaluated the response of GI-PDNEC to 
treatment and analysed their overall prognosis on the 
basis of specific parameters and particularly the Ki67 LI 
[7, 8, 18]. Similarly to WDNETs, where the site of origin 
within the GI-tract may be of significance for the overall 
prognosis of these tumours, there is evidence that this 
may also apply for PDNEC [7, 8]. 
Two histological variants of PDNEC, small and large 
cell, are defined; combined forms with elements of non-
neuroendocrine carcinoma (mostly adenomatous or 
squamous) have also been recognised. However, there 
are no studies demonstrating that such a distinction is of 
relevant clinical significance [7]. PDNEC include small-
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proximately the size of three lymphocytes, with scant 
cytoplasm and round or spindle-shaped nuclei that 
exhibit nuclear modelling [9]. GI-SCC typically have > 
10 mitoses/10 high power fields (HPF) (average 40–50), 
lymphovascular invasion and Ki67 LI > 20% (but usu-
ally higher than 75%) [3, 8]. Similarly, the large cell 
variant of GI-PDNEC consists of larger cells with more 
abundant cytoplasm and also exhibits similarities to 
SCLC but shows reduced expression of the transcription 
factor CDX2 and high microsatellite instability [9]. In an 
analysis of 44 cases of large-cell PDNEC that included 13 
patients with GI-PDNEC and 15 with unknown primary 
origin, high mitotic count, low expression of neuroendo-
crine markers and a Bcl-2/Bax ratio > 1 were found to be 
unfavourable prognostic markers [21]. In a more recent 
study where histopathologic analysis was available in 
305 patients with GI-PDNEC, 115 were found to have 
small-cell morphology mostly encountered in oesopha-
geal and rectal tumours, and 148 had non-small-cell 
morphology mostly encountered in colonic primaries 
[7]. In the same study, it was shown that the Ki67 LI was 
> 55% mostly in primary gut tumours, whereas lower 
values were found in pancreatic PDNEC; however, 
there were neither Ki67 nor CgA immunostaining dif-
ferences between small and non-small (large) PDNEC 
[7]. As the majority of these tumours are not associated 
with distinct clinical syndromes, tumour cells lack im-
munopositivity for hormonal products [1, 9]. 
Besides immunoreactivity for CgA and synapto-
physin, PDNEC may also be positive for carcinoem-
bryonic antigen (CEA) [9]. Keratin expression is 
common and in contrast to SCLC in which thyroid 
transcription factor-1 (TTF-1) is found to be present in 
85-100% of cases, in GI-PDNEC it is only occasionally 
positive in approximately 17% of cases [22]. Although 
the precise aetiology of these neoplasms is largely 
unknown, several molecular aberrations have been 
detected such as overexpression of p53, telomerase 
activation and retinoblastoma (Rb) gene loss [9, 23, 
24]. Recent evidence has also suggested that these 
tumours are more likely to develop through chro-
mosomal rather than microsatellite instability [25]. 
Due to the late introduction of a TNM staging sys-
tem in PDNEC, previous studies have been based on 
the American Joint Committee on Cancer consisting 
of two staging categories, limited disease, defined as a 
tumour contained within a localised anatomic region, 
with or without regional lymph node involvement, 
and extensive disease, defined as a tumour outside the 
locoregional boundaries [3, 26]. 
Clinical presentation according  
to location and site of origin
Patients with PDNEC can present with either localised 
regional or distant disease; however, most have already 
extensive disease at diagnosis [3, 7, 9, 13]. As the great 
majority of these tumours are not associated with a clini-
cal syndrome, clinical presentation is guided by the local 
effects of the tumour and the effects that it may exert on 
adjacent tissues [3, 7]. In a large study including 305 pa-
tients, only 3% were found to have symptoms related to 
a secretory syndrome [7]. A further distinctive feature of 
extra-pulmonary PDNEC is the low propensity for devel-
opment of brain metastases compared to SCLC [1, 3, 9, 14].
PDNEC of the stomach: These tumours account for ap-
proximately 6% of gastric NETs with a mean age at diag-
nosis of 64 years [27, 28]. The majority of tumours present 
as single lesions evenly distributed in the stomach with an 
average size of 4.2–6.3 cm [29, 30]. Common presenting 
symptoms are abdominal pain, GI-bleed and upper GI 
discomfort. Gastric PDNEC may contain an additional 
adenocarcinomatous or squamous component [29]. 
PDNEC of the duodenum: These are rare tumours 
primarily located in the ampulla of Vater [31] account-
ing for 2-3% of ampullary tumours [32]. The majority 
of patients present with jaundice and abdominal pain; 
mean tumour size is 2.5 cm and may be associated with 
adjacent mucosa adenomas in up to 50% of cases [33]. 
PDNEC of the pancreas: These tumours account for 
1% of all malignant pancreatic tumours and are pre-
dominantly located in the pancreatic head, measuring 
4 cm in diameter, invading surrounding organs and/or 
having developed metastases [34]. Common presenting 
symptoms include jaundice, weight loss, abdominal 
pain and more rarely symptoms attributed to hormo-
nal hyperproduction such as Cushing’s syndrome and 
carcinoid syndrome [1]. 
Figure 3. Ki67 labelling index in poorly differentiated neuro-
endocrine carcinoma
Rycina 3. Wskaźnik aktywności proliferacyjnej Ki67 w nisko-
zróżnicowanych rakach neuroendokrynnych
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PDNEC of the colon and rectum: There is a paucity 
of information regarding this presence of PDNEC in 
this region, although this specific localisation may be 
associated with an overall worse prognosis [7, 9]. This 
is evident by the finding that although the prevalence 
of rectal carcinoids has increased, mainly as a result 
of the increased investigational procedures, the number 
of PDNEC has remained low [9]. This may also be re-
lated to the fact that some tumours may have been mis-
diagnosed as adenocarcinomas prior to the introduction 
of the new classification systems. The nationwide SEER 
study on rare tumours of the colon and rectum from the 
USA showed a significant increase of NET histologies, 
albeit without distinguishing between small and large 
cell variants, over the past decade [35]. However, data on 
the true incidence of PDNEC in relation to carcinomas 
with NE differentiation is still lacking [35]. 
PDNEC of unknown origin and localised in lymph 
nodes: In a significant number of PDNEC, the primary 
site of origin may be impossible to recognise [3, 7, 9]. 
However, since the majority of extra-pulmonary PD-
NEC arise from the GI tract, it is possible that most of 
them are probably GI-PDNEC. A previous study has 
raised some concern as to whether the localisation of 
PDNEC only in the lymph nodes represents a distinct 
clinical entity [11]. These authors identified 28 patients 
with such a diagnosis who were found to have a bet-
ter outcome compared to patients with pulmonary or 
extra-pulmonary PDNEC [11]. The majority (75%) of 
these patients presented with limited disease localised 
only in the lymph nodes, showed a good response to 
surgery, chemotherapy or radiotherapy, and had an 
overall survival of 79% at three years [11]. Further stud-
ies are necessary to delineate if such a distinct entity 
exists, although a study evaluating large cell PDNEC 
showed that patients presenting with single lymph 
node involvement had a much better outcome [21]. 
Diagnostic procedures
Following the diagnosis of a PDNEC, it is important to 
exclude a primary pulmonary lesion and assess if the pa-
tient has limited or extensive disease. Diagnosed studies 
are aimed at affected areas employing modalities such as 
endoscopy and morphological imaging as well as staging 
procedures. There are no specific differences in the applica-
tion of upper and/or lower GI endoscopic procedures and 
other conventional imaging modalities used to identify 
these tumours compared to other GEP-NETs that have 
recently extensively been described by ENETS [36, 37]. 
Imaging
Computed tomography (CT) and magnetic resonance 
imaging (MRI) scans are used to delineate local tumour 
extension particularly in the liver and bones [13]. How-
ever, there are no comparative studies evaluating the 
diagnostic accuracy of these modalities. In contrast to 
WDNETs, where sstr scintigraphy (SRS), either with 
111Inlabelled-octreotide or more recently 68Gallium-
DOTATE/TOC, is used for their diagnosis and staging, 
this modality is not equally useful in PDNEC as the 
majority of these tumours lack sstr expression [13, 16]. 
These tumours demonstrate intense metabolic activ-
ity, reflecting their proliferative activity, and therefore 
18F-fluorodeoxyglucose positron emission tomography 
(18F-FDG PET) imaging is used for baseline staging and 
for monitoring response to treatment [13, 16]. This was 
shown in a recent prospective study of 96 patients 
with mostly GEP-NETs, 13 of whom had a Ki67 LI > 
15%, who underwent imaging with 18F-FDG PET, SRS, 
and 123I-MIBG (metaiodobenzylguanidine) obtaining 
sensitivities of 92%, 69% and 46% respectively [16]. 
There is however increasing data demonstrating that 
SRS may be positive, albeit at a less intensity, in up to 
60% of patients with PDNEC [8, 16, 21]. In a recent 
study, when SRS was performed in a large cohort of 
patients with GI-PDNEC, a high uptake was mainly 
found in primary pancreatic tumours; however, in that 
study SRS was performed mainly in patients with a 
relatively lower Ki67 LI albeit within the G3 grading 
group [7]. Because expression of sstr may indicate a 
less aggressive tumour behaviour, some authors have 
suggested that SRS could also be performed in PDNEC 
patients as it could represent a prognostic and predic-
tive marker of response to specific chemotherapy (i.e. 
temozolomide) [38, 39]. It could even indicate whether 
peptide receptor radionuclide therapy (PRRT) could be 
an additional therapeutic option [38, 39]. Although this 
may specifically hold true for PDNEC with relatively 
low Ki67 LI, there is currently no data evaluating this 
form of treatment in patients with PDNEC and posi-
tive SRS [40]. 
Biochemical markers
The universal biochemical marker for NETs CgA is of 
relatively small value for either diagnosing or moni-
toring the response to treatment in PDNEC. This has 
been shown by a number of studies and it is probably 
related to the de-differentiation of these tumours [41]. 
In contrast, NSE may exert a relatively higher diagnostic 
utility [6, 42]. More importantly, a study investigating 
CgA and NSE sensitivity by tumour grading indicated 
that large cell and small cell NETs showed a statistically 
significant higher NSE sensitivity compared to G1 and 
G2 NETs, whereas the opposite effect was noticed with 
CgA levels [43]. In a recent retrospective study, CgA 
measurement was available in 188/305 patients with 
GI-PDNEC and was found to be elevated in approxi-
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mately two thirds of them [7]. In the same study, urine-
5-hydroxyindoloacetic acid (5HIAA) was measured in 
94 patients and was found to be elevated in 24; however, 
most of these patients had tumours with relatively low 
Ki67 LI values [7]. Choice of tumour markers in patients 
with NETs is dependent on the histological grade, but 
both CgA and NSE could be used for the initial evalua-
tion of the tumour; when found abnormal, their serial 
assessment could be valuable in monitoring the disease 
and response to treatment [41].
Newer evolving markers are currently being in-
vestigated. Progastrin-releasing peptide [proGRP) is 
a precursor form of gastrin-releasing peptide (GRP, 
mammalian bombesin) that is widely distributed 
throughout the GI and pulmonary tract [44]. ProGRP 
and cytokeratin fragments (CKfr, CK8, 18, 19) have 
been shown to be associated with survival in patients 
with SCLC and may also be of value in patients with 
extra-pulmonary PDNEC [43]. Furthermore, in a com-
prehensive comparative study of CgA, NSE, proGRP 
and cytokeratin fragments involving 280 patients with 
WDNET, 42 with LCNEC, 251 with SCNEC and 282 
healthy controls, proGRP showed the highest sensitivity 
(73%) at 95% specificity in patients with SCNEC [43]. 
In a multivariate survival analysis, both Ckfr and NSE 
were associated with survival [43, 44]. 
Prognostic parameters
Patients can present with either localised, regional or 
distant disease [13] exerting a relatively poor prognosis 
with median survival durations of 34 months in patients 
with localised, and 14 and 5 months in patients with 
regional and distant disease, respectively [45]. Previous 
studies have documented that tumour extension (lim-
ited vs. extensive disease) and patient’s performance 
status are strong predictors of survival [3, 7]. This has 
recently been verified by a large retrospective study 
including 305 patients with GI-PDNEC [7].
Treatment
Based on some similarities of PDNEC to SCLC, 
adjuvant chemotherapy treatment of SCLC includ-
ing a platinum-based agent, cisplatin or carboplatin 
depending on patient comorbidities, and etoposide, 
is recommended (National Comprehensive Cancer 
Network clinical practice guidelines; ‘Neuroendocrine 
Tumours’ in www.nccn.org). Similar combinations of 
platinum-based agents and etoposide have also been 
used in metastatic GI-PDNEC, although some have 
questioned this rationale as there are many differences 
between pulmonary and GI PDNEC [3, 10, 13] (Table I). 
Two prospective studies have evaluated the efficacy of 
this regimen in patients with GI-PDNEC. In the first, 
18 patients with metastatic PDNEC were treated, pro-
ducing a response rate of 67% in patients with previ-
ously documented progressive disease with responses 
lasting for eight months and an overall median sur-
vival of 19 months [46]. In the second study, 53 patients 
(41 with PDNEC among whom 20 with GI-PDNEC) 
were treated with the same regimen showing a response 
rate of 42% with response duration of nine months and 
a median survival of 15 months [47]. However, in these 
studies, not only GI but various other extra-pulmonary 
sites of origin of primary tumours were included, 
precluding the extraction of precise data [7, 12, 13]. 
However, several other retrospective studies have 
validated the efficacy of this regimen in GI-PDNEC 
(Table IV). The regimen mostly involves the combina-
tion of etoposide 100 mg/m2 on day 1 for three days and 
cisplatin 100 mg/m2 on day 1 given by 2-h intravenous 
infusion, administered every 21 days [47]. 
Recent data has also shown that the combination of 
cisplatin and irinotecan (four-week cycles of 60mg/m2 
irinotecan on days 1, 8, and 15 and 60mg/m2 cisplatin 
on day 1) in 44 patients with various extra-pulmonary 
PDNEC showed a response rate of 64% at first line and 
a progression free survival (PFS) of 7.3 months; there 
was a significant relationship with NSE elevation and 
poor survival [48]. The same combination was used in 
12 patients with metastatic or recurrent PDNEC of the 
stomach, obtaining a response rate of 75%, a median 
PFS of 212 days and a median survival time of 697 days 
[49]. Following the analysis of a large number of patients 
with GI-PDNEC, it became evident that there was some 
heterogeneity of the responses obtained based on the 
primary location and proliferation rate [7]. In a previ-
ous retrospective study, 21 patients with hepatobiliary 
and pancreatic PDNEC were treated with the combi-
nation of cisplatin 80mg/m2 given intravenously on 
day 1 and etoposide 100mg/m2 intravenously on days 
1–3 repeated every 3–4 weeks [12]; only three patients 
had a partial response (14%) whereas the median PFS 
was 1.8 months and median overall survival (OS) 
5.8 months. The optimal duration of chemotherapy has 
not been clearly defined, although 4–6 cycles are usu-
ally administered; however, it has not been established 
whether treatment beyond four cycles offers a survival 
benefit [13]. A recent multicentre study has shown that 
there was no difference in response regarding tumour 
morphology or positive CgA IHC and/or the various 
platinum-based chemotherapy schedules used, i.e. 
cisplatin v. carboplatin [7].
While the mammalian target of rapamycin (mTOR) 
signalling pathway is a target for WDNET with the 
mTOR inhibitor everolimus, PDNEC are usually ex-
cluded from clinical trials (RADIANT 2, RADIANT 
68
Uptade in diagnosis and management of GI-PDNEC  Anna Koumarianou et al.
SZ
K
O
LE
N
IE
 
PO
D
Y
PL
O
M
O
W
E
Table IV. Summary of response rates obtained in patients with extra-pulmonary poorly differentiated NETs treated with 
etoposide- and platinum-based regimens 
Tabela IV. Zestawienie danych dotyczących odsetka odpowiedzi na leczenie uzyskiwanych u pacjentów z pozapłucnymi nisko- 
zróżnicowanymi NET leczonymi wg schematów obejmujących etopozyd i pochodną platyny
Treatment Number of patients Primary site Response rate Response duration Reference
Cisplatin 45 mg/m2  
days 2, 3 and etoposide  
130 mg/m2 days 1, 2, 3
18 advanced  
disease
Any 67% 8 months [46]
Cisplatin 100 mg/m2 day 1  
and etoposide 100 mg/m2  
days 1, 2, 3
53 advanced  
disease
Any 41.5% 4.5–23.5 months 
(median 9.2)
[47]
Cisplatin and etoposide  
± paclitaxel
18 advanced  
disease
Any 17% 6.3 months [88]
Cisplatin and etoposide 8 advanced  
disease
Colorectal 62% 4.5 months [89]
Cisplatin 80 mg/m2 day 1  
and etoposide 100 mg/m2  
days 1, 2, 3
21 advanced  
disease
Pancreas and 
hepatobiliary
14% 2 months [12]
Cisplatin or carboplatin  
and etoposide or CAV
64 limited and 
advanced disease
GI-SCNEC 36% 8 (4–16) months [14]
Cisplatin or carboplatin  
and etoposide
252 advanced  
disease
GI-NEC 31% 11 months median 
survival
[7]
Cisplatin 45 mg/m2  
days 2, 3 and etoposide  
100 mg/m2 days 1, 2, 3
36 advanced  
disease
Any 55–80% 8–11 months [90]
Cisplatin and Irinotecan 22 advanced  
disease
Stomach 75% 7 months [49]
Cisplatin 60 mg/m2 day 1  
and irinotecan 60 mg/m2  
days 1, 8, 15 
50 limited and 
advanced  
disease
Any 64% 7.3 months [48]
GI — gastrointestinal; NEC — neuroendocrine carcinoma; SCNEC — small cell neuroendocrine carcinoma
3) due to their aggressive nature [50, 51]. However, 
recent data has shown that mTOR expression can be 
found in all NETs irrespective of the primary site of 
origin and/or proliferation rate as defined by the ki67 
LI [52]. Therefore, the role of everolimus in this subset 
of patients may need to be defined further. Following 
the finding that PDNEC may show positive uptake 
in SRS, a recent study focused on the results follow-
ing PRRT with 177Lu-DOTA-octreotate in 81 patients 
with respect to proliferation rate [38]. Response rates 
in patients with Ki67 LI up to 20% were almost 80% 
(partial response and stable disease); however, only 
2/7 patients with Ki67 LI > 20% exhibited a similar 
response rate, and in accordance with previous studies 
a positive correlation of uptake intensity and outcome 
was noted [38, 53]. However, as the proliferation rate 
can be heterogeneous even within the same tumour, 
fractionated therapy with PRRT could be considered 
a treatment option in patients with apparent PDNEC 
and high sstr expression [39]. 
Localised disease
PDNEC are characterised by a high tendency for 
metastatic dissemination even if localised, as almost 
all patients who were treated with surgery alone 
had recurrent disease [3, 13]. Several studies have 
evaluated the overall outcome in patients with 
PDNEC who were treated with surgery alone with 
an intention to obtain a surgical cure of the disease. 
However, none of the patients who underwent such 
a surgical procedure was found to be alive at three 
and five years of follow-up, compared to 100% and 
85% of patients who had WDNETs and had the same 
treatment [54, 55]. It has therefore been suggested 
that even an apparent complete surgical resection 
adjuvant treatment with radiotherapy and/or chemo-
therapy should be given to eradicate any residual 
disease [13]. However, due to the rarity of cases there 
is no information regarding the need for such an 
approach in patients with relatively low Ki67 values 
albeit within the G3 range. 
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Second line therapy
Despite initial response, a significant number of 
patients will develop progressive disease. However, 
very few studies have evaluated response rates to 
second line therapy and most data is derived from 
similar data from relapsed SCLC that exhibit response 
rates ranging between 0% and 20% [13]. Patients 
that developed relatively late recurrences (more 
than 3–6 months) may receive retreatment with a 
platinum agent and etoposide or irinotecan [13,48], 
whereas oral topotecan has been shown to improve 
by three months median survival in patients with 
SCLC [56]. Such an approach may be useful in pa-
tients with GI-PDNEC, particularly those who have 
a relatively low performance status. Other agents 
that could be used based on experience from SCLC 
are paclitaxel, docetaxel, vinorelbine and gemcitabine 
[13, 57]. However, when progression develops fol-
lowing first line therapy, the disease is usually very 
aggressive despite the administration of several 
different second line regimens and patients may 
experience a relatively short survival [8]. Recently it 
was shown that the response rate in 26 patients who 
experienced progression to the same regimen was 
42% (15% partial response and 27% stable disease), 
whereas the response rates following second-line 
chemotherapy with other agents in 84 patients was 
51% (18% partial response and 33% stable disease), 
and after third-line chemotherapy in 29 patients 
41% [7]. Based on the experience that temozolomide 
could be active in a small number of patients with 
PDNEC [18], a recent retrospective study evaluated 
the effect of temozolomide either alone or in combi-
nation with capecitabine or bevacizumab as second 
line therapy in patients with mostly GI-PDNEC. 
A response rate of 33% was obtained with a median 
duration of response of 19 months, whereas 71% of 
patients had at least stabilisation of the previously 
progressive disease; median PFS was six months and 
median OS was 22 months [8, 58]. Patients with Ki67 
LI of < 60%, positive immunohistochemistry for CgA, 
positive SRS, and lack of response to first-line therapy 
seemed to respond better to the administration of te-
mozolomide [8]. Adding capecitabine or bevacizumab 
to temozolomide did not seem to have any additional 
effect, although this should be regarded with caution 
as the number of patients included in each group was 
small [8]. Evaluation of O6methylguanidine-DNA 
methyltransferase (MGMT) expression, an enzyme 
that when present may predict poor response to 
temozolomide, did not seem to be necessary for 
predicting the response to treatment, as it was only 
positive in 1/17 tested patients [8]. Although this 
study has several limitations, as only patients with 
good performance status would be considered candi-
dates for further therapy, it provides some evidence 
for using temozolomide particularly in patients with 
not extremely high Ki67 LI values who are probably 
those not responding to the first line treatment with 
cisplatin and etoposide.
Predictors of response — survival
A number of previous studies have shown differences 
between these tumours and SCLC [3, 7, 10, 11, 14, 59]. 
However, as in patients with SCLC, the median sur-
vival in patients not receiving chemotherapy is only 
one month, justifying aggressive management similar 
to SCLC using chemotherapy in such patients [7]. Al-
though there may be a selection bias, as patients with 
low performance status were more likely not to be 
treated, chemotherapy is a powerful tool to improve 
survival necessitating the need to identify predictors of 
response and survival [3, 7, 13, 55, 57]. Several studies 
have shown that the extent of the disease and patient’s 
performance status are the best predictors of response [3, 
7, 13, 55, 57]. Recently, a multicentre retrospective study 
has provided useful information regarding predictors 
of response in a large cohort of 305 patients with GI-
PDNEC [7]. Ki67 LI emerged as an important predictor 
of response. The best cut-off value regarding response 
rate for Ki67 by ROC analysis was 55%; responses were 
lower when Ki67 LI was > 55% (15% vs. 42%). Patients 
with worse performance status had a higher percentage 
of immediate disease progression than patients with 
good performance status (61% v. 265) [7]. 
In addition, a recent prospective study evaluated 
the role of 18F-FDG PET as a predictor of survival in 98 
patients with GEP-NETs. Fourteen of these patients had 
a PDNEC and in 13 of them 18F-FDG PET was positive. 
Although the authors did not provide specific informa-
tion in this particular group of patients it was shown 
that a SUVmax > 9 and a high Ki67 LI were significant 
predictors of OS with a hazard ratio of 8.8 and 2.6 re-
spectively; however, in multivariate analysis a SUVmax 
> 3 was the only predictor of PFS [16]. Based on this 
data, it is highly possible that measurement of SUVmax 
in patients with PDNEC may prove to be a valuable 
predictor of either response to treatment or survival 
besides Ki67 LI [16]. 
Ki67 LI may also predict those with a survival 
benefit, as many more patients with a Ki67 < 55% 
were alive compared to only 7% when Ki67 > 55% [7]. 
Furthermore, patients with primary colon tumours 
had a shorter median survival compared to patients 
with pancreatic tumours (8 v. 15 months) in a large 
multicentre study [7]. This outcome was not related 
to either cisplatin or carboplatin use, histopathologic 
morphology (small v. large cell) or intensity of CgA im-
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munostaining [7]. Performance status has also evolved 
as a powerful predictor of survival, as patients with 
good performance status exhibited the best survival [7]. 
Following the results of a multivariate analysis, apart 
from the site of the primary tumour and performance 
status, blood levels of platelets and LDH were also 
strong predictors of survival: patients with the best 
performance status and normal platelet and LDH levels 
had a median survival of 26 months [7]. 
Summary
Poorly differentiated neuroendocrine carcinomas 
(PDNEC) are rare tumours that constitute a hetero-
geneous group of NEC with an overall aggressive 
behaviour associated with a short survival that have 
traditionally been subdivided histologically into 
large and small cell PDNEC. The majority of these 
tumours present with extensive disease that is best 
documented with the use of 18F-FDG PET scan that 
can also be used to guide response to treatment (Fig. 
4). Although SRS is not useful for staging of PDNEC, 
it may be of prognostic value reflecting the hetero-
geneity of these tumours and the need to develop 
further tools to clarify the biological behaviour of 
each tumour within that group. No ideal currently 
available tumour markers for PDNEC exist, although 
CgA may be more useful in LC PDNEC whereas NSE 
may be more useful in SC-PDNEC; however, there 
seems to be no difference regarding response to 
treatment and overall prognosis between these two 
histological variants. 
The prognosis of PDNEC is associated with the 
extent of the disease, performance status of the patient, 
and the origin of the primary lesion, whereas absolute 
Ki67 LI expression may be a prognostic indicator of 
the response to treatment and of overall biological 
behaviour (Fig. 4). Platinum- and etoposide-based 
chemotherapy seems to obtain significant responses 
and improve survival in PDNEC and should be the 
first-line therapy. Other regimens also seem to have 
some activity but the majority of patients will develop 
recurrent disease necessitating further therapy with 
a variety of chemotherapeutic agents, albeit achiev-
ing lower response rates. For some of these patients, 
second line therapy with temozolomide may evolve 
as a reasonable option although this needs to be clari-
fied by further prospective studies. The majority of 
clinical available data is based on a retrospective series 
of patients and thus most currently existing clinical 
guidelines are based on a low level of evidence data 
(expert opinion), making it urgent that larger multicen-
tre studies be performed. Recently it has been argued 
that GI-PDNEC are not a single disease entity and 
additional clinical and molecular data are required to 
identify specific subgroups. However, as GI-PDNEC 
constitute a heterogeneous group of aggressive tu-
mours, treatment should be initiated early when the 
performance status is still adequate as it represents a 
very strong indicator of survival. 
Figure 4. Treatment algorithm for poorly differentiated neuroendocrine carcinomas. Data derived from [7, 8, 16]; PDNEC — poorly 
differentiated neuroendocrine carcinoma; LI — labelling index; SRS — somatostatin receptor scintigraphy; 18F-FDG PET — 
18F-fluorodeoxyglucose positron emission tomography; Chemotherapy — platinum + etoposide or irinotecan
Rycina 4. Algorytm postępowania w niskozróżnicowanych rakach neuroendokrynnych
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